San Antonio, Texas — According to state and local development sources, Quest Diagnostics plans to invest $4,000,000.00 to build out 21,645 square feet of new space in San Antonio. The company plans to occupy the new space at 607 E. Sonterra Blvd, Suite 300 in San Antonio, on or about February 1, 2026. According to the company website Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the worlds largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the companys approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the worlds 2nd largest provider of clinical trials testing for new pharmaceuticals.

To learn more about Quest Diagnostics, visit http://www.questdiagnostics.com/

Company Contact:
Steve Rusckowski, Chief Executive Officer
800-222-0446

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.